FCER2 抗体
(Fc Fragment of IgE, Low Affinity II, Receptor For (CD23) (FCER2))
The protein encoded by this gene is a B-cell specific antigen, and a low-affinity receptor for IgE. It has essential roles in B cell growth and differentiation, and the regulation of IgE production. This protein also exists as a soluble secreted form, then functioning as a potent mitogenic growth factor. Alternatively spliced transcript variants encoding different isoforms have been described for this gene.[provided by RefSeq, Jul 2011].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| FCER2 抗体 (AA 50-331) (Fluoro594) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| FCER2 抗体 (AA 50-331) (PE) | 人, 小鼠, 大鼠 | 兔 Polyclonal |
|
|
|
| FCER2 抗体 (AA 48-284) (PE) | 人, 大鼠 | 兔 Polyclonal |
|
|
|
| FCER2 抗体 (AA 48-321) (CF®640R) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) (CF®405S) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) (CF®594) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) (CF®488A) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) (CF®740) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) (CF®568) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) (CF®647) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) | 人 | 小鼠 Monoclonal |
|
|
|
| Recombinant FCER2 抗体 (C-Term) | 人 | 兔 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) | 人 | 兔 Monoclonal |
|
|
|
| FCER2 抗体 (AA 150-331) (APC) | 小鼠 | 豚鼠 Polyclonal |
|
|
|
| FCER2 抗体 (AA 150-331) (FITC) | 小鼠 | 兔 Polyclonal |
|
|
|
| FCER2 抗体 (AA 150-331) (PE) | 小鼠 | 兔 Polyclonal |
|
|
|
| FCER2 抗体 (AA 150-331) | 小鼠 | 兔 Polyclonal |
|
|
|
| FCER2 抗体 (AA 48-321) (FITC) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 48-321) | 人 | 小鼠 Monoclonal |
|
|
|
| FCER2 抗体 (AA 150-331) | 小鼠 | 兔 Polyclonal |
|
|
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Fluoro594
- 抗体亚型
- IgG
- 抗原表位
- AA 50-331
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
- 适用
- 人, 小鼠, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- PE
- 抗体亚型
- IgG
- 抗原表位
- AA 50-331
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- 适用
- 人, 大鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- PE
- 抗体亚型
- IgG
- 抗原表位
- AA 48-284
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- IHC (fp) (Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- FCER2-3592
- 标记
- CF®640R
- 抗体亚型
- IgG2b, kappa
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- IHC (fp) (Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- FCER2-3592
- 标记
- CF®405S
- 抗体亚型
- IgG2b, kappa
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- IHC (fp) (Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- FCER2-3592
- 标记
- CF®594
- 抗体亚型
- IgG2b, kappa
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- IHC (fp) (Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- FCER2-3592
- 标记
- CF®488A
- 抗体亚型
- IgG2b, kappa
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- IHC (fp) (Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- FCER2-3592
- 标记
- CF®740
- 抗体亚型
- IgG2b, kappa
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- IHC (fp) (Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- FCER2-3592
- 标记
- CF®568
- 抗体亚型
- IgG2b, kappa
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- IHC (fp) (Immunohistochemistry (Formalin-fixed Paraffin-embedded Sections): 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- FCER2-3592
- 标记
- CF®647
- 抗体亚型
- IgG2b, kappa
- 抗原表位
- AA 48-321
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- WB (Western Blotting: 所列应用)
- Neut (Neutralization: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- MM0164-2C23
- 标记
- unconjugated
- 抗体亚型
- IgG1
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- WB (Western Blotting: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Monoclonal
- 克隆
- RM406
- 标记
- unconjugated
- 蛋白类型
- Recombinant Antibody
- 抗体亚型
- IgG
- 抗原表位
- C-Term
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Monoclonal
- 克隆
- C9
- 标记
- unconjugated
- 抗体亚型
- IgG1 kappa
- 抗原表位
- AA 48-321
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- 适用
- 小鼠
- 宿主
- 豚鼠
- 克隆形成能力
- Polyclonal
- 标记
- APC
- 抗原表位
- AA 150-331
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- 适用
- 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- FITC
- 抗原表位
- AA 150-331
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- 适用
- 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- PE
- 抗原表位
- AA 150-331
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- 适用
- 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 150-331
Primary Antibody
- FACS (Flow Cytometry: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- C12
- 标记
- FITC
- 抗体亚型
- IgG1 kappa
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- WB (Western Blotting: 所列应用)
- IP (Immunoprecipitation: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Monoclonal
- 克隆
- C12
- 标记
- unconjugated
- 抗体亚型
- IgG1 kappa
- 抗原表位
- AA 48-321
Primary Antibody
- IHC (Immunohistochemistry: 所列应用)
- WB (Western Blotting: 所列应用)
- IP (Immunoprecipitation: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 150-331
Latest Publications for our FCER2 抗体
: "B cells sustain inflammation and predict response to immune checkpoint blockade in human melanoma. ..." in: Nature communications, Vol. 10, Issue 1, pp. 4186, (2019) (PubMed).
: "Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction." in: Nature communications, Vol. 9, Issue 1, pp. 7, (2018) (PubMed).
: "The follicular dendritic cell network in secondary follicles of human palatine tonsils and spleens." in: Histochemistry and cell biology, Vol. 135, Issue 4, pp. 327-36, (2011) (PubMed).
: "Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 186, Issue 8, pp. 4967-72, (2011) (PubMed).
: "B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis." in: Journal of clinical immunology, Vol. 30, Issue 1, pp. 99-105, (2010) (PubMed).
: "Comparison of CD23 staining patterns in Merkel cell carcinoma and non-cutaneous small cell carcinoma." in: Journal of cutaneous pathology, Vol. 36, Issue 2, pp. 206-10, (2009) (PubMed).
: "Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China." in: Environmental and molecular mutagenesis, Vol. 50, Issue 4, pp. 285-90, (2009) (PubMed).
: "Fluid flow in distensible vessels." in: Clinical and experimental pharmacology & physiology, Vol. 36, Issue 2, pp. 206-16, (2009) (PubMed).
: "Immunophenotypic variations in hairy cell leukemia." in: American journal of clinical pathology, Vol. 125, Issue 2, pp. 251-9, (2006) (PubMed).
: "Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 18, Issue 3, pp. 398-405, (2005) (PubMed).
: "Trapping IgE in a closed conformation by mimicking CD23 binding prevents and disrupts FcεRI interaction." in: Nature communications, Vol. 9, Issue 1, pp. 7, (2018) (PubMed).
: "The follicular dendritic cell network in secondary follicles of human palatine tonsils and spleens." in: Histochemistry and cell biology, Vol. 135, Issue 4, pp. 327-36, (2011) (PubMed).
: "Natural IgM is required for suppression of inflammatory arthritis by apoptotic cells." in: Journal of immunology (Baltimore, Md. : 1950), Vol. 186, Issue 8, pp. 4967-72, (2011) (PubMed).
: "B-cell reconstitution and BAFF after alemtuzumab (Campath-1H) treatment of multiple sclerosis." in: Journal of clinical immunology, Vol. 30, Issue 1, pp. 99-105, (2010) (PubMed).
: "Comparison of CD23 staining patterns in Merkel cell carcinoma and non-cutaneous small cell carcinoma." in: Journal of cutaneous pathology, Vol. 36, Issue 2, pp. 206-10, (2009) (PubMed).
: "Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China." in: Environmental and molecular mutagenesis, Vol. 50, Issue 4, pp. 285-90, (2009) (PubMed).
: "Fluid flow in distensible vessels." in: Clinical and experimental pharmacology & physiology, Vol. 36, Issue 2, pp. 206-16, (2009) (PubMed).
: "Immunophenotypic variations in hairy cell leukemia." in: American journal of clinical pathology, Vol. 125, Issue 2, pp. 251-9, (2006) (PubMed).
: "Primary breast diffuse large B-cell lymphoma shows a non-germinal center B-cell phenotype." in: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc, Vol. 18, Issue 3, pp. 398-405, (2005) (PubMed).
Aliases for FCER2 抗体
Fc fragment of IgE receptor II (FCER2) 抗体Fc fragment of IgE receptor II (Fcer2) 抗体
BLAST-2 抗体
CD23 抗体
CD23A 抗体
CLEC4J 抗体
FCE2 抗体
Fcer2a 抗体
IGEBF 抗体
您还需要查找其他产品吗？
You are here:
